Cargando…
Elagolix: a promising oral GnRH antagonist for endometriosis-associated pain
Autores principales: | Dun, Erica C., Taylor, Hugh S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725085/ https://www.ncbi.nlm.nih.gov/pubmed/29245894 http://dx.doi.org/10.18632/oncotarget.22381 |
Ejemplares similares
-
Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study
por: Carr, Bruce, et al.
Publicado: (2013) -
Comparison of GnRH Agonist, GnRH Antagonist, and GnRH Antagonist Mild Protocol of Controlled Ovarian Hyperstimulation in Good Prognosis Patients
por: Stimpfel, Martin, et al.
Publicado: (2015) -
Gonadotropin-Releasing Hormone (GnRH)/GnRH Receptors and Their Role in the Treatment of Endometriosis
por: Resta, Christina, et al.
Publicado: (2023) -
Combination GnRH antagonists for endometriosis: Balancing efficacy with side effects
por: Whitaker, L.H.R., et al.
Publicado: (2022) -
Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment
por: Lv, Jialu, et al.
Publicado: (2020)